Moleculin Biotech

MBRX

Market cap $2.83M

MBRX Hedge Fund Activity: Q1 2026 in Review

20 of the 8,134 institutional investors tracked by Wall St. Rank reported a position in Moleculin Biotech (MBRX) for Q1 2026, worth a combined $348K — up 10% from $315K a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new MBRX positions and 3 closed out — a net gain of 4 holders — while 4 added to existing stakes and 2 trimmed.

The largest buyer was Sabby Management, opening a new position worth an estimated $248K. The largest seller was Citadel Advisors, exiting entirely with an estimated $110K sold.

• 20 institutional investors held Moleculin Biotech (MBRX) as of Q1 2026, up from 17 in Q4 2025.
• Funds reported $348K of Moleculin Biotech stock for Q1 2026, up 10% quarter-over-quarter.
• 7 funds opened new Moleculin Biotech positions in Q1 2026 and 3 closed out, a net change of +4 holders.
• The largest Moleculin Biotech buyer in Q1 2026 was Sabby Management, an estimated $248K added.
• The largest Moleculin Biotech seller in Q1 2026 was Citadel Advisors, an estimated $110K sold.

Based on aggregated 13F filings for Q1 2026.